ArticleNPJ Parkinson's disease2026
Tissue-specific mutation of pink-1 jointly induces intestinal dysfunction and contributes to dopaminergic neuron degeneration.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In patients with Parkinson's disease (PD), intestinal dysfunction represents one of the predominant non-motor symptoms and typically manifests at the earliest stages of the disease. However, the underlying causes of intestinal dysfunction and its impact on disease progression remain to be fully elucidated. Using Caenorhabditis elegans as a model, we found that loss-of-function mutations in pink-1 delayed defecation rhythm, resulting in aberrant intestinal colonization upon the pathogenic bacterium Pseudomonas aeruginosa PA14 exposure, which subsequently accelerates dopaminergic neurodegeneration. Mechanistically, PINK-1 in neurons regulated dgk-1 expression, a key positive regulator of defecation, through direct binding of the downstream transcription factor CEH-22 in the dgk-1 promoter region. Concurrently, pink-1 mutation in the intestine suppresses the glutathione metabolic pathway and impairs the clearance of reactive oxygen species (ROS) induced by pathogenic accumulation. Notably, the regulatory role of PINK-1 is evolutionarily conserved in mammalian cells. Our findings demonstrate that pink-1 mutation in the C. elegans model exhibits the constipation phenotype similar to that observed in early-stage PD patients and weakens resistance to microbial infections via inactivating glutathione metabolic pathway. These results clarify a causal link between intestinal dysfunction and neurodegeneration, providing novel insights into the role of PINK-1 in PD pathogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.